AP-238 AP238 CAS: 4204-01-7

CAS NO: 4204-01-7
Our products are for scientific research use only
AP-238 AP238
Chemical Name: 2,6-Dimethyl-1-(1-oxopropyl)-4-(3-phenyl-2-propenyl)piperazine
Molecular Formula: C18H26N2O
Formula Weight: 286.41
CAS No.: 4204-01-7
Description Review
Description
Our products are for scientific research use only





AP-238, also known as N-((2S)-2-amino-3-methylbutanoyl)-L-valine, is a chemical compound that has gained attention in scientific research due to its potential for use in pain management. In this article, we will explore AP-238 in detail, covering its chemical properties, potential health benefits, potential side-effects, and other essential information.

Chemical Name: The chemical name of AP-238 is N-((2S)-2-amino-3-methylbutanoyl)-L-valine. It is an organic compound with a molecular formula of C11H21N3O4 and a formula weight of 263.31 g/mol.

CAS No: The CAS number of AP-238 is 4204-01-7.

Top Searched Keywords on Google and Synonyms on google: The following are the top searched keywords and synonyms of AP-238 on Google:

  • AP-238
  • AP238
  • 4204-01-7
  • N-((2S)-2-amino-3-methylbutanoyl)-L-valine
  • Pain Management
  • Analgesic
  • Opioid

Health Benefits: There are potential health benefits of AP-238, as determined through in vitro and animal studies, which show that AP-238 has potent analgesic properties, making it useful for pain management.

Potential Effects and Mechanisms: The potential effects and mechanisms of AP-238 depend on the specific use and application of the compound.

  1. Analgesic Effects: AP-238 binds to the mu-opioid receptor, a key protein that functions as a receptor for endogenous opioids in the central nervous system. It produces a potent analgesic effect, i.e., pain relief.

Safety: Currently, there is not enough data to confirm the safety of AP-238 for human use. It is a compound that is still under investigation and considered experimental.

Side-Effects: The potential side-effects of AP-238 are largely unknown since scientific research is still in its early stages. However, like any other opioid medication, AP-238 could cause physical dependence or addiction if taken in large doses or over long periods of time.

Dosage Information: Currently, there is no established recommended dosage of AP-238 for human use. Given that scientific research is still in its early stages, it is unknown what dose is safe for use in humans. Hence, it is vital to monitor the dose of AP-238 administered during research particularly before administering to human.

In conclusion, AP-238 is a novel compound with the potential for use as an analgesic in pain management. Its potency and select

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code